A detailed history of Jacobs & CO transactions in Novartis Ag stock. As of the latest transaction made, Jacobs & CO holds 2,750 shares of NVS stock, worth $266,282. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,750
Previous 2,750 -0.0%
Holding current value
$266,282
Previous $292,000 8.22%
% of portfolio
0.03%
Previous 0.03%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 12, 2024

SELL
$95.27 - $108.47 $21,435 - $24,405
-225 Reduced 7.56%
2,750 $266,000
Q4 2023

Jan 17, 2024

BUY
$92.27 - $101.54 $13,840 - $15,231
150 Added 5.31%
2,975 $300,000
Q2 2022

Jul 19, 2022

SELL
$80.52 - $93.75 $120,780 - $140,625
-1,500 Reduced 34.68%
2,825 $238,000
Q1 2022

Apr 14, 2022

SELL
$80.11 - $90.62 $80,110 - $90,620
-1,000 Reduced 18.78%
4,325 $379,000
Q2 2021

Jul 15, 2021

BUY
$85.24 - $94.15 $51,144 - $56,490
600 Added 12.7%
5,325 $485,000
Q4 2019

Jan 29, 2020

BUY
$84.35 - $95.37 $126,524 - $143,055
1,500 Added 46.51%
4,725 $447,000
Q1 2019

Apr 29, 2019

SELL
$75.32 - $86.15 $18,830 - $21,537
-250 Reduced 7.19%
3,225 $310,000
Q3 2017

Nov 14, 2017

BUY
$74.14 - $77.27 $257,636 - $268,513
3,475
3,475 $298,000

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $208B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Jacobs & CO Portfolio

Follow Jacobs & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs & CO with notifications on news.